{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:09:40Z","timestamp":1791338980896,"version":"4.3.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T00:00:00Z","timestamp":1673654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 109-2320-B-038-009"],"award-info":[{"award-number":["MOST 109-2320-B-038-009"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 110-2320-B-006-039"],"award-info":[{"award-number":["MOST 110-2320-B-006-039"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nitric oxide-releasing drugs are used for cardiovascular diseases; however, their effects on the tumor immune microenvironment are less clear. Therefore, this study explored the impact of nitric oxide donors on tumor progression in immune-competent mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effects of three different nitric oxide-releasing compounds (SNAP, SNP, and ISMN) on tumor growth were studied in tumor-bearing mouse models. Three mouse tumor models were used: B16F1 melanoma and LL2 lung carcinoma in C57BL\/6 mice, CT26 colon cancer in BALB\/c mice, and LL2 lung carcinoma in NOD\/SCID mice. After nitric oxide treatment, splenic cytokines and lymphocytes were analyzed by cytokine array and flow cytometry, and tumor-infiltrating lymphocytes in the TME were analyzed using flow cytometry and single-cell RNA sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Low doses of three exogenous nitric oxide donors inhibited tumor growth in two immunocompetent mouse models but not in NOD\/SCID immunodeficient mice. Low-dose nitric oxide donors increase the levels of splenic cytokines IFN-\u03b3 and TNF-\u03b1 but decrease the levels of cytokines IL-6 and IL-10, suggesting an alteration in Th2 cells. Nitric oxide donors increased the number of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells with activation gene signatures, as indicated by single-cell RNA sequencing. Flow cytometry analysis confirmed an increase in infiltrating CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and dendritic cells. The antitumor effect of nitric oxide donors was abolished by depletion of CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, indicating the requirement for CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Tumor inhibition correlated with a decrease in a subtype of protumor macrophages and an increase in a subset of Arg1-positive macrophages expressing antitumor gene signatures. The increase in this subset of macrophages was confirmed by flow cytometry analysis. Finally, the combination of low-dose nitric oxide donor and cisplatin induced an additive cancer therapeutic effect in two immunocompetent animal models. The enhanced therapeutic effect was accompanied by an increase in the cells expressing the gene signature of NK cell.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Low concentrations of exogenous nitric oxide donors inhibit tumor growth in vivo by regulating T cells and macrophages. CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells are essential for antitumor effects. In addition, low-dose nitric oxide donors may be combined with chemotherapeutic drugs in cancer therapy in the future.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-022-02590-0","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T21:02:45Z","timestamp":1673643765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Repurposing nitric oxide donating drugs in cancer therapy through immune modulation"],"prefix":"10.1186","volume":"42","author":[{"given":"Chung-Yen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangga","family":"Anuraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Peng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Yang","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ping","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Dang Khoa","family":"Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Fang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Hsuan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiang-Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Hsuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Derg","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,14]]},"reference":[{"key":"2590_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell."},{"key":"2590_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13046-020-01586-y","volume":"39","author":"F Galli","year":"2020","unstructured":"Galli F, et al. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39:89.","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"2590_CR3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, et al. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol."},{"key":"2590_CR4","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1101\/gad.314617.118","volume":"32","author":"H Gonzalez","year":"2018","unstructured":"Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267\u201384.","journal-title":"Genes Dev."},{"key":"2590_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, et al. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359\u201367.","journal-title":"Br. J. Cancer."},{"key":"2590_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33:547\u201362.","journal-title":"Cancer Cell."},{"key":"2590_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat. Med."},{"key":"2590_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/345346a0","volume":"345","author":"H Bult","year":"1990","unstructured":"Bult H, et al. Nitric oxide as an inhibitory non-adrenergic non-cholinergic neurotransmitter. Nature. 1990;345:346\u20137.","journal-title":"Nature."},{"key":"2590_CR9","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1126\/science.1720572","volume":"254","author":"EM Schuman","year":"1991","unstructured":"Schuman EM, Madison DV. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science. 1991;254:1503\u20136.","journal-title":"Science."},{"key":"2590_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"F Wu","year":"2021","unstructured":"Wu F, et al. Single cell transcriptomics reveals lineage trajectory of retinal ganglion cells in wild-type and Atoh7-null retinas. Nat Commun. 2021;12:1\u201320.","journal-title":"Nat. Commun."},{"key":"2590_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1161\/01.RES.58.4.531","volume":"58","author":"U Forstermann","year":"1986","unstructured":"Forstermann U, et al. Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Circ Res. 1986;58:531\u20138.","journal-title":"Circ. Res."},{"key":"2590_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4103\/0970-9185.142799","volume":"30","author":"DG Hottinger","year":"2014","unstructured":"Hottinger DG, et al. Sodium nitroprusside in 2014: A clinical concepts review. J Anaesth Clin Pharm. 2014;30:462\u201371.","journal-title":"J. Anaesth. Clin. Pharm."},{"key":"2590_CR13","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1073\/pnas.89.7.3030","volume":"89","author":"T Nguyen","year":"1992","unstructured":"Nguyen T, et al. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci U S A. 1992;89:3030\u20134.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2590_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.niox.2005.12.005","volume":"15","author":"T Waldow","year":"2006","unstructured":"Waldow T, et al. Nitric oxide donor-induced persistent inhibition of cell adhesion protein expression and NFkappaB activation in endothelial cells. Nitric Oxide. 2006;15:103\u201313.","journal-title":"Nitric Oxide."},{"key":"2590_CR15","doi-asserted-by":"publisher","first-page":"e1204506","DOI":"10.1080\/2162402X.2016.1204506","volume":"5","author":"IM Sektioglu","year":"2016","unstructured":"Sektioglu IM, et al. Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection. Oncoimmunology. 2016;5:e1204506.","journal-title":"Oncoimmunology."},{"key":"2590_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.humimm.2016.12.001","volume":"78","author":"J Chen","year":"2017","unstructured":"Chen J, et al. Suppression of T cells by myeloid-derived suppressor cells in cancer. Hum Immunol. 2017;78:113\u20139.","journal-title":"Hum Immunol."},{"key":"2590_CR17","doi-asserted-by":"publisher","first-page":"113899","DOI":"10.1016\/j.bcp.2020.113899","volume":"176","author":"N Nath","year":"2020","unstructured":"Nath N, Kashfi K. Tumor associated macrophages and \u2018NO.\u2019 Biochem Pharmacol. 2020;176:113899.","journal-title":"Biochem. Pharmacol."},{"key":"2590_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/carcin\/bgt034","volume":"34","author":"AJ Burke","year":"2013","unstructured":"Burke AJ, et al. The yin and yang of nitric oxide in cancer progression. Carcinogenesis. 2013;34:503\u201312.","journal-title":"Carcinogenesis."},{"key":"2590_CR19","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/s41565-019-0570-3","volume":"14","author":"Y-C Sung","year":"2019","unstructured":"Sung Y-C, et al. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat Nanotechnol. 2019;14:1160\u20139.","journal-title":"Nat. Nanotechnol."},{"key":"2590_CR20","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1021\/acsnano.1c09048","volume":"16","author":"W Jiang","year":"2022","unstructured":"Jiang W, et al. Nitric oxide induces immunogenic cell death and potentiates cancer immunotherapy. ACS Nano. 2022;16:3881\u201394.","journal-title":"ACS Nano."},{"key":"2590_CR21","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1749-6632.2002.tb04080.x","volume":"962","author":"J-L Burgsud","year":"2002","unstructured":"Burgsud J-L, Ongini E, Del Soldata P. Nitric oxide-releasing drugs. Ann NY Acad Sci. 2002;962:360\u201371.","journal-title":"Ann. N.Y. Acad. Sci"},{"key":"2590_CR22","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1097\/00004872-199917120-00015","volume":"17","author":"GS Stokes","year":"1999","unstructured":"Stokes GS, et al. A controlled study of the effects of isosorbide mononitrate on arterial blood pressure and pulse wave form in systolic hypertension. J Hypertens. 1999;17:1767\u201373.","journal-title":"J. Hypertens."},{"key":"2590_CR23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0002-8703(77)80012-4","volume":"93","author":"BK Yeh","year":"1977","unstructured":"Yeh BK, et al. Sodium nitroprusside as a coronary vasodilator in man: I. Effect of intracoronary sodium nitroprusside on coronary arteries, angina pectoris, and coronary blood flow. Am Heart J. 1977;93:610\u20136.","journal-title":"Am. Heart J."},{"key":"2590_CR24","first-page":"4793","volume":"9","author":"WE Boden","year":"2015","unstructured":"Boden WE, et al. Role of short-acting nitroglycerin in the management of ischemic heart disease. Drug Des Devel Ther. 2015;9:4793\u2013805.","journal-title":"Drug Des Devel Ther."},{"key":"2590_CR25","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36:411\u201320.","journal-title":"Nat. Biotechnol."},{"key":"2590_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","volume":"179","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, et al. Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829-845.e20.","journal-title":"Cell."},{"key":"2590_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang L, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181:442-459.e29.","journal-title":"Cell."},{"key":"2590_CR28","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/stke.2001.86.pl1","volume":"2001","author":"SR Jaffrey","year":"2001","unstructured":"Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE. 2001;2001:pl1.","journal-title":"Sci STKE."},{"key":"2590_CR29","doi-asserted-by":"publisher","first-page":"8525","DOI":"10.1073\/pnas.0407294102","volume":"102","author":"A Mart\u00ednez-Ruiz","year":"2005","unstructured":"Mart\u00ednez-Ruiz A, et al. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci U S A. 2005;102:8525\u201330.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2590_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21:345\u201359.","journal-title":"Nat. Rev. Cancer."},{"key":"2590_CR31","doi-asserted-by":"publisher","first-page":"e7475","DOI":"10.1371\/journal.pone.0007475","volume":"4","author":"D Pilling","year":"2009","unstructured":"Pilling D, et al. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One. 2009;4:e7475\u2013e7475.","journal-title":"PLoS One."},{"key":"2590_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","volume":"52","author":"J-C Beltra","year":"2020","unstructured":"Beltra J-C, et al. Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52:825-841.e8.","journal-title":"Immunity."},{"key":"2590_CR33","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692.","journal-title":"Nat Commun."},{"key":"2590_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.bbamcr.2010.12.010","volume":"1813","author":"Z Culig","year":"2011","unstructured":"Culig Z. Cytokine disbalance in common human cancers. Biochim Biophys Acta-Mol Cell Res. 2011;1813:308\u201314.","journal-title":"Biochim. Biophys. Acta-Mol. Cell Res."},{"key":"2590_CR35","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","volume":"78","author":"H Tsukamoto","year":"2018","unstructured":"Tsukamoto H, et al. Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018;78:5011\u201322.","journal-title":"Cancer Res."},{"key":"2590_CR36","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-10-0356","volume":"16","author":"L Gattinoni","year":"2010","unstructured":"Gattinoni L, Ji Y, Restifo NP. Wnt\/\u03b2-Catenin signaling in T-cell immunity and cancer immunotherapy. Clin Cancer Res. 2010;16:4695\u2013701.","journal-title":"Clin. Cancer Res."},{"key":"2590_CR37","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","volume":"13","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13:107.","journal-title":"J. Hematol. Oncol."},{"key":"2590_CR38","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP Bdttcher","year":"2018","unstructured":"Bdttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4:784\u201392.","journal-title":"Trends Cancer."},{"key":"2590_CR39","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.dci.2010.12.015","volume":"35","author":"Z Wu","year":"2011","unstructured":"Wu Z, Hu T, Kaiser P. Chicken CCR6 and CCR7 are markers for immature and mature dendritic cells respectively. Dev Comp Immunol. 2011;35:563\u20137.","journal-title":"Dev Comp Immunol."},{"key":"2590_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol."},{"key":"2590_CR41","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41467-020-14433-7","volume":"11","author":"EM Palmieri","year":"2020","unstructured":"Palmieri EM, et al. Nitric oxide orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase. Nat Commun. 2020;11:698.","journal-title":"Nat. Commun."},{"key":"2590_CR42","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.7150\/thno.26888","volume":"8","author":"SP Arlauckas","year":"2018","unstructured":"Arlauckas SP, et al. Arg1 expression defines immunosuppressive subsets of tumor-associated macrophages. Theranostics. 2018;8:5842\u201354.","journal-title":"Theranostics."},{"key":"2590_CR43","doi-asserted-by":"publisher","first-page":"e002548","DOI":"10.1136\/jitc-2021-002548","volume":"9","author":"S Liu","year":"2021","unstructured":"Liu S, et al. S100A4 enhances protumor macrophage polarization by control of PPAR-\u03b3-dependent induction of fatty acid oxidation. J Immunother Cancer. 2021;9:e002548.","journal-title":"J. Immunother. Cancer."},{"key":"2590_CR44","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.4049\/jimmunol.180.9.6168","volume":"180","author":"T Bosschaerts","year":"2008","unstructured":"Bosschaerts T, et al. Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P. J Immunol. 2008;180:6168\u201375.","journal-title":"J. Immunol."},{"key":"2590_CR45","doi-asserted-by":"publisher","first-page":"e0145342","DOI":"10.1371\/journal.pone.0145342","volume":"10","author":"KA Jablonski","year":"2015","unstructured":"Jablonski KA, et al. Novel markers to delineate murine M1 and M2 macrophages. PLoS One. 2015;10:e0145342.","journal-title":"PLoS One."},{"key":"2590_CR46","doi-asserted-by":"publisher","first-page":"7884","DOI":"10.1074\/jbc.M113.522037","volume":"289","author":"AJ Freemerman","year":"2014","unstructured":"Freemerman AJ, et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem. 2014;289:7884\u201396.","journal-title":"J Biol Chem."},{"key":"2590_CR47","doi-asserted-by":"publisher","first-page":"e0116644","DOI":"10.1371\/journal.pone.0116644","volume":"10","author":"F Szulzewsky","year":"2015","unstructured":"Szulzewsky F, et al. Glioma-associated microglia\/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015;10:e0116644\u2013e0116644.","journal-title":"PLoS One."},{"key":"2590_CR48","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.4049\/jimmunol.1201064","volume":"189","author":"MM Escribese","year":"2012","unstructured":"Escribese MM, et al. The prolyl hydroxylase PHD3 identifies proinflammatory macrophages and Its expression is regulated by Activin A. J Immunol. 2012;189:1946.","journal-title":"J. Immunol."},{"key":"2590_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y. Targeting macrophages in cancer immunotherapy. Signal Transduct Target Ther. 2021;6:127.","journal-title":"Signal Transduct. Target. Ther."},{"key":"2590_CR50","doi-asserted-by":"crossref","unstructured":"Jaynes JM, et al. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci Transl Med. 2020;12:eaax6337.","DOI":"10.1126\/scitranslmed.aax6337"},{"key":"2590_CR51","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1172\/JCI76099","volume":"125","author":"CW Barrett","year":"2015","unstructured":"Barrett CW, et al. Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage. J Clin Invest. 2015;125:2646\u201360.","journal-title":"J. Clin. Invest."},{"key":"2590_CR52","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1165\/rcmb.2015-0012OC","volume":"53","author":"AA Tarique","year":"2015","unstructured":"Tarique AA, et al. Phenotypic, functional, and plasticity features of classical and alternatively activated human macrophages. Am J Respir Cell Mol Biol. 2015;53:676\u201388.","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2590_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12885-020-6588-y","volume":"20","author":"Y Hattori","year":"2020","unstructured":"Hattori Y, et al. A phase I\/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer. BMC Cancer. 2020;20:115.","journal-title":"BMC Cancer."},{"key":"2590_CR54","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","volume":"379","author":"L Paz-Ares","year":"2018","unstructured":"Paz-Ares L, et al. Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer. N Engl J Med. 2018;379:2040\u201351.","journal-title":"N. Engl. J. Med."},{"key":"2590_CR55","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","volume":"606","author":"X Guan","year":"2022","unstructured":"Guan X, et al. Androgen receptor activity in T cells limits checkpoint blockade efficacy. Nature. 2022;606:791\u20136.","journal-title":"Nature."},{"key":"2590_CR56","doi-asserted-by":"publisher","first-page":"19445","DOI":"10.1039\/C5RA00270B","volume":"5","author":"J Fu","year":"2015","unstructured":"Fu J, et al. Identification of nitric oxide-releasing derivatives of oleanolic acid as potential anti-colon cancer agents. RSC Adv. 2015;5:19445\u201354.","journal-title":"RSC Adv."},{"key":"2590_CR57","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41419-018-0465-5","volume":"9","author":"P Zheng","year":"2018","unstructured":"Zheng P, et al. Tumor-associated macrophages-derived exosomes promote the migration of gastric cancer cells by transfer of functional Apolipoprotein E. Cell Death Dis. 2018;9:434.","journal-title":"Cell Death Dis."},{"key":"2590_CR58","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1158\/0008-5472.CAN-20-3929","volume":"81","author":"SB Kemp","year":"2021","unstructured":"Kemp SB, et al. Apolipoprotein E promotes immune suppression in pancreatic cancer through NF-\u03baB-mediated production of CXCL1. Cancer Res. 2021;81:4305\u201318.","journal-title":"Cancer Res."},{"key":"2590_CR59","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1161\/HYPERTENSIONAHA.107.092049","volume":"50","author":"T Yamashita","year":"2007","unstructured":"Yamashita T, et al. Apoptosis signal-regulating kinase-1 Is involved in vascular endothelial and cardiac remodeling caused by nitric oxide deficiency. Hypertension. 2007;50:519\u201324.","journal-title":"Hypertension."},{"key":"2590_CR60","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1056\/NEJMc062800","volume":"355","author":"FJ Larsen","year":"2006","unstructured":"Larsen FJ, et al. Effects of dietary nitrate on blood pressure in healthy volunteers. N Engl J Med. 2006;355:2792\u20133.","journal-title":"N. Engl. J. Med."},{"key":"2590_CR61","doi-asserted-by":"publisher","first-page":"12097","DOI":"10.1073\/pnas.192209799","volume":"99","author":"DP Ballou","year":"2002","unstructured":"Ballou DP, et al. Revisiting the kinetics of nitric oxide (NO) binding to soluble guanylate cyclase: The simple NO-binding model is incorrect. Proc Natl Acad Sci U S A. 2002;99:12097.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2590_CR62","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.niox.2009.07.002","volume":"21","author":"CN Hall","year":"2009","unstructured":"Hall CN, Garthwaite J. What is the real physiological NO concentration in vivo? Nitric Oxide. 2009;21:92\u2013103.","journal-title":"Nitric Oxide."},{"key":"2590_CR63","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s12272-022-01389-z","volume":"45","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Ji YR, Lee YM. Crosstalk between angiogenesis and immune regulation in the tumor microenvironment. Arch Pharm Res. 2022;45:401\u201316.","journal-title":"Arch Pharm Res."},{"key":"2590_CR64","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/(SICI)1521-4141(199908)29:08<2498::AID-IMMU2498>3.0.CO;2-M","volume":"29","author":"W Niedbala","year":"1999","unstructured":"Niedbala W, et al. Effects of nitric oxide on the induction and differentiation of Th1 cells. Eur J Immunol. 1999;29:2498\u2013505.","journal-title":"Eur. J. Immunol."},{"key":"2590_CR65","first-page":"2702","volume":"6","author":"J Nakashima","year":"2000","unstructured":"Nakashima J, et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res. 2000;6:2702\u20136.","journal-title":"Clin. Cancer Res."},{"key":"2590_CR66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/978-3-030-62658-7_5","volume":"1302","author":"L Portella","year":"2021","unstructured":"Portella L, Bello AM, Scala S. CXCL12 signaling in the tumor microenvironment. Adv Exp Med Biol. 2021;1302:51\u201370.","journal-title":"Adv Exp Med Biol."},{"key":"2590_CR67","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","volume":"117","author":"M Sivina","year":"2011","unstructured":"Sivina M, et al. CCL3 (MIP-1\u03b1) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011;117:1662\u20139.","journal-title":"Blood."},{"key":"2590_CR68","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41408-022-00675-9","volume":"12","author":"B Aslan","year":"2022","unstructured":"Aslan B, et al. Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022;12:80.","journal-title":"Blood Cancer J."},{"key":"2590_CR69","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","volume":"1231","author":"N Mukaida","year":"2020","unstructured":"Mukaida N, Sasaki SI, Baba T. CCL4 signaling in the tumor microenvironment. Adv Exp Med Biol. 2020;1231:23\u201332.","journal-title":"Adv Exp Med Biol."},{"key":"2590_CR70","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2590_CR71","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378:2078\u201392.","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02590-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02590-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T22:07:46Z","timestamp":1673647666000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02590-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,14]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2590"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02590-0","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,14]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by Institutional Animal Care and Use Committee (IACUC), National Cheng Kung University (IACUC number: 109268 and 110227).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}